Brokerages forecast that Medpace Holdings, Inc. (NASDAQ:MEDP – Get Rating) will report sales of $346.73 million for the current fiscal quarter, Zacks Investment Research reports. Three analysts have issued estimates for Medpace’s earnings. The lowest sales estimate is $344.50 million and the highest is $350.09 million. Medpace posted sales of $278.29 million during the same quarter last year, which would indicate a positive year over year growth rate of 24.6%. The firm is scheduled to announce its next quarterly earnings results on Monday, January 1st.
On average, analysts expect that Medpace will report full year sales of $1.41 billion for the current fiscal year, with estimates ranging from $1.38 billion to $1.42 billion. For the next fiscal year, analysts forecast that the business will post sales of $1.60 billion, with estimates ranging from $1.48 billion to $1.70 billion. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side analysts that follow Medpace.
Medpace (NASDAQ:MEDP – Get Rating) last posted its earnings results on Monday, April 25th. The company reported $1.69 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.26 by $0.43. Medpace had a net margin of 16.47% and a return on equity of 24.17%. The firm had revenue of $330.90 million during the quarter, compared to analyst estimates of $327.09 million. During the same quarter in the prior year, the business posted $1.17 EPS. The business’s revenue was up 27.3% compared to the same quarter last year.
NASDAQ MEDP opened at $133.57 on Friday. Medpace has a 1 year low of $126.94 and a 1 year high of $231.00. The firm has a market cap of $4.49 billion, a price-to-earnings ratio of 24.92 and a beta of 1.48. The company has a fifty day moving average price of $154.09 and a 200-day moving average price of $182.80.
Several large investors have recently modified their holdings of MEDP. Liberty Wealth Management LLC boosted its holdings in shares of Medpace by 67.1% in the 3rd quarter. Liberty Wealth Management LLC now owns 137 shares of the company’s stock worth $28,000 after buying an additional 55 shares during the last quarter. Confluence Wealth Services Inc. purchased a new position in shares of Medpace in the 4th quarter worth about $36,000. USA Financial Portformulas Corp purchased a new position in shares of Medpace in the 3rd quarter worth about $62,000. Clearstead Advisors LLC boosted its holdings in shares of Medpace by 126.0% in the 3rd quarter. Clearstead Advisors LLC now owns 339 shares of the company’s stock worth $64,000 after buying an additional 189 shares during the last quarter. Finally, Sageworth Trust Co of South Dakota purchased a new position in shares of Medpace in the 4th quarter worth about $87,000. 96.88% of the stock is currently owned by institutional investors.
About Medpace (Get Rating)
Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.
See Also
- Get a free copy of the StockNews.com research report on Medpace (MEDP)
- Why is Chevron Stock Falling After Strong Earnings?
- MarketBeat: Week in Review 4/25 – 4/29
- Apple’s Numbers Complete Trifecta
- Rogers Communication Stock Should Be Launching Higher
- O’Reilly Automotive Hits A Pothole
Get a free copy of the Zacks research report on Medpace (MEDP)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.
